Gilles Salles
#72,536
Most Influential Person Now
French scientist
Gilles Salles's AcademicInfluence.com Rankings
Gilles Sallesphilosophy Degrees
Philosophy
#4425
World Rank
#6932
Historical Rank
Logic
#1876
World Rank
#2737
Historical Rank
Download Badge
Philosophy
Why Is Gilles Salles Influential?
(Suggest an Edit or Addition)According to Wikipedia, Gilles Salles is a French haematologist who joined the Memorial Sloan Kettering Cancer Center in New York in 2020 after a career as a French University Professor & Medical Doctor in Lyon University Hospitals . He is specialized in hematologic malignancies, in particular non-Hodgkin and Hodgkin lymphomas.
Gilles Salles's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms. (2016) (5445)
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. (2002) (2551)
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. (2002) (1983)
- Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. (2005) (1312)
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma (2019) (1180)
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (2011) (964)
- PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. (2014) (945)
- The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. (2003) (838)
- Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. (2004) (822)
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. (2001) (545)
- Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. (2000) (491)
- Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). (1996) (484)
- Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. (2000) (453)
- Prognostic significance of survivin expression in diffuse large B-cell lymphomas. (2000) (417)
- Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32) (1999) (400)
- Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. (2006) (400)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (2019) (394)
- Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. (1997) (381)
- Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience (2017) (327)
- Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. (1997) (324)
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. (2008) (321)
- Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. (2007) (320)
- Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. (2004) (315)
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial (2011) (314)
- Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. (2012) (306)
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. (2016) (297)
- Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. (1998) (293)
- Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network (2016) (289)
- Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 (2007) (287)
- Primary thyroid lymphoma is a heterogeneous disease. (2002) (284)
- Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. (2000) (284)
- Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 (2007) (275)
- Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. (2014) (269)
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial (2020) (267)
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. (2016) (264)
- Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma (2017) (261)
- Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (2013) (256)
- High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. (2008) (252)
- Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2006) (245)
- Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. (2007) (240)
- Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. (2008) (239)
- Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. (2012) (235)
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) (232)
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. (2016) (229)
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. (2013) (229)
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (2018) (222)
- Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. (2015) (221)
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. (2020) (219)
- Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. (2002) (209)
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study (2016) (208)
- Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. (2016) (207)
- International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
- Mantle cell lymphoma: a retrospective study of 121 cases (1998) (204)
- MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. (2015) (197)
- Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. (2011) (194)
- Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. (2013) (193)
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. (2020) (192)
- Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. (2003) (191)
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. (2012) (191)
- Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. (2004) (190)
- Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. (1995) (189)
- Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. (2009) (187)
- Early event status informs subsequent outcome in newly diagnosed follicular lymphoma (2016) (180)
- International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. (1999) (180)
- Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) (2008) (179)
- Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. (2012) (175)
- Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study (2016) (174)
- Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. (2011) (171)
- 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. (2013) (168)
- Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision of the World Health Organization classi fi cation of lymphoid neoplasms (2016) (166)
- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
- International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. (1999) (164)
- Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies (1998) (158)
- Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas (2006) (157)
- Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. (2013) (153)
- Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma (1996) (150)
- Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. (2002) (149)
- Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). (2019) (149)
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (2019) (147)
- Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. (2017) (144)
- High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation (1998) (143)
- Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. (2014) (142)
- Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. (2008) (141)
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma (2014) (140)
- Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. (2016) (136)
- Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. (2017) (135)
- Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. (2017) (133)
- Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial (2016) (132)
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study (2019) (131)
- Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. (2014) (128)
- Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. (2008) (128)
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations. Section 9. t(14;18) with BCL2-IGH rearrangement. (2003) (127)
- Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? (2008) (127)
- Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. (2010) (127)
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. (2009) (125)
- A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. (2018) (124)
- Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. (2004) (124)
- High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. (2015) (123)
- Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. (2019) (123)
- Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. (2009) (122)
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial (2021) (122)
- Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. (2008) (122)
- Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. (1994) (122)
- Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. (2019) (118)
- Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs. (1991) (118)
- A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2017) (117)
- Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial (2013) (117)
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). (2013) (114)
- High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation (2014) (113)
- Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. (2010) (113)
- t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. (2014) (113)
- Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. (2000) (113)
- Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphoma (2001) (112)
- Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. (1997) (111)
- Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. (2017) (110)
- Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. (2007) (109)
- Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs (2011) (108)
- A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts (2018) (107)
- Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2017) (105)
- High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. (1998) (105)
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (2021) (105)
- Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. (2001) (103)
- p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. (2002) (102)
- Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. (2014) (101)
- Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study (2011) (100)
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes (2015) (100)
- The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab (2008) (98)
- International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. (2020) (98)
- Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) (2020) (97)
- From genetics to the clinic: a translational perspective on follicular lymphoma (2018) (97)
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. (2021) (97)
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies (2018) (97)
- Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. (1997) (96)
- Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party (2013) (96)
- The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association (2015) (96)
- Angioimmunoblastic T-Cell Lymphoma: Clinical and Laboratory Features at Diagnosis in 77 Patients (2007) (95)
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. (2019) (94)
- Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers (2017) (93)
- Frequency and significance of anemia in non-Hodgkin's lymphoma patients. (1998) (92)
- Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. (2005) (92)
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. (2021) (91)
- Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. (1993) (91)
- Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. (2009) (91)
- Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. (2007) (91)
- Human germinal center transcriptional programs are de-synchronized in B cell lymphoma (2018) (90)
- Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy (2013) (90)
- Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. (2002) (90)
- Two new miR‐16 targets: caprin‐1 and HMGA1, proteins implicated in cell proliferation (2009) (90)
- Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. (2009) (88)
- Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. (2009) (88)
- A clinicopathological study of nodal marginal zone B‐cell lymphoma. A report on 21 cases (2006) (88)
- Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma (2004) (86)
- Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. (2010) (86)
- Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. (2017) (85)
- The Lymphoid Variant of Hypereosinophilic Syndrome (2014) (85)
- Early steps of follicular lymphoma pathogenesis. (2011) (83)
- Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B‐cell lymphoma (2016) (83)
- Clinical features, prognosis and treatment of follicular lymphoma. (2007) (82)
- Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. (2018) (81)
- Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA (2011) (81)
- Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. (2006) (78)
- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma (2016) (77)
- Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. (2019) (77)
- Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma (2013) (76)
- Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. (2016) (76)
- Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA (2012) (75)
- CLLD8/KMT1F Is a Lysine Methyltransferase That Is Important for Chromosome Segregation* (2010) (75)
- Rituximab Added αIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients. (2004) (74)
- Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. (2018) (74)
- Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. (2017) (72)
- Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. (2017) (71)
- Diffuse Large B-Cell Lymphoma. (2021) (71)
- Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. (1998) (71)
- Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. (2006) (71)
- Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center (2020) (71)
- CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases (2010) (71)
- Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. (2006) (70)
- Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases (2016) (68)
- Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment (2014) (67)
- Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. (2010) (67)
- Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. (2018) (67)
- R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study (2009) (67)
- Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. (2000) (67)
- Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. (2020) (66)
- Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. (2016) (66)
- Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. (2010) (65)
- Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. (2015) (65)
- Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. (2018) (64)
- CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. (2021) (64)
- MALT lymphomas: pathogenesis can drive treatment. (2011) (63)
- Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. (2013) (63)
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. (2015) (63)
- The European Hematology Association Roadmap for European Hematology Research: a consensus document. (2016) (62)
- Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome (1999) (62)
- Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. (2016) (62)
- Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. (2012) (61)
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (61)
- Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. (2012) (61)
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study (2017) (61)
- High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia (2012) (59)
- Prevalence and pattern of antinuclear autoantibodies in 347 patients with non‐Hodgkin's lymphoma (2003) (59)
- INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS (2017) (59)
- ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). (2019) (58)
- The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma (2017) (58)
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2011) (57)
- High total metabolic tumor volume at baseline predicts survival independent of response to therapy (2020) (57)
- EZH2 alterations in follicular lymphoma: biological and clinical correlations (2017) (57)
- The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium (2014) (56)
- Cyclin-dependent kinase 1 expression is inhibited by p16INK4a at the post-transcriptional level through the microRNA pathway (2011) (56)
- Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. (2009) (54)
- WHO ) classification of lymphoid neoplasms (2016) (54)
- Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials (2021) (54)
- Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases (2005) (54)
- Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. (2007) (52)
- Long term outcome of patients with hairy cell leukemia treated with pentostatin (1999) (52)
- Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma (2013) (52)
- Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA (2019) (52)
- Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. (2019) (51)
- Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. (2011) (50)
- Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma (2009) (49)
- Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association (2017) (49)
- Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years. (2006) (48)
- Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. (2018) (48)
- Chemotherapy of non-Hodgkin's aggressive lymphomas. (1994) (48)
- Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. (1995) (48)
- Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. (2017) (48)
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (48)
- Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. (1999) (48)
- Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma (2002) (48)
- Autoimmune thrombocytopenic purpura after autologous stem cell transplantation (2003) (47)
- CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis. (1992) (47)
- Prevention of high dose L-PAM-induced mucositis by cryotherapy. (1994) (46)
- Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years (2017) (46)
- Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? (2005) (46)
- International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial (2015) (46)
- Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). (2020) (46)
- Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. (2018) (46)
- A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease (2008) (45)
- Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma (2006) (45)
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2021) (45)
- Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. (2017) (44)
- Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux (2019) (44)
- Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study (2015) (44)
- Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. (2012) (44)
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel (2018) (43)
- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS (2017) (43)
- Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group (2016) (43)
- Transcriptional Activation of hTERT, the Human Telomerase Reverse Transcriptase, by Nuclear Factor of Activated T Cells* (2009) (43)
- Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. (1999) (43)
- Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group (2016) (42)
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) (42)
- Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. (2016) (42)
- 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients. (2007) (42)
- Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). (2000) (42)
- Indolent nonfollicular lymphomas: characteristics, treatment, and outcome. (1999) (41)
- A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features (2020) (41)
- Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. (2003) (40)
- Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma (2017) (40)
- Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma (2013) (40)
- Obinutuzumab in hematologic malignancies: lessons learned to date. (2015) (40)
- Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium (2017) (40)
- Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. (2016) (40)
- Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (2021) (40)
- Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma (2016) (39)
- Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. (2019) (39)
- Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT (2016) (39)
- Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series (2017) (39)
- The tumor necrosis factor signaling complex: choosing a path toward cell death or cell proliferation. (1998) (39)
- Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma (2012) (39)
- Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. (2020) (39)
- The superoxide dismutase content in erythrocytes predicts short‐term toxicity of high‐dose cyclophosphamide (2001) (39)
- CD3−CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder (2015) (39)
- Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index (2010) (38)
- Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (2014) (38)
- High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP. (2020) (38)
- Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies (2022) (38)
- Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). (2006) (38)
- Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. (2009) (38)
- Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. (2012) (38)
- Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma (2013) (38)
- Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study (2014) (37)
- PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study (2014) (37)
- Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis (2017) (37)
- Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site. (1992) (37)
- Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma (2005) (37)
- Monitoring NK cell activity in patients with hematological malignancies (2013) (36)
- Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B‐cell lymphoma (SRPL) (2011) (36)
- Predictors of prescription errors involving anticancer chemotherapy agents. (2012) (36)
- Splenic marginal zone lymphoma: current knowledge and future directions. (2012) (36)
- Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification (2011) (35)
- Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study. (2017) (35)
- Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. (2013) (35)
- MicroRNA expression profile in splenic marginal zone lymphoma (2012) (35)
- Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo. (1993) (35)
- An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s Syndrome (2016) (35)
- Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001 (2003) (35)
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma (2017) (35)
- Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. (2020) (35)
- An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) (2018) (34)
- Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? (2013) (34)
- Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. (2012) (34)
- Telomere uncapping during in vitro T‐lymphocyte senescence (2009) (34)
- Does surgery belong to medical history for gastric lymphomas? (1997) (34)
- Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL). (2009) (34)
- CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial (2018) (33)
- Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma (2020) (33)
- Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials (2017) (33)
- Diffuse large B-cell lymphoma: new targets and novel therapies (2021) (33)
- Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study (2018) (33)
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma (2016) (32)
- Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin’s lymphoma (1999) (31)
- Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data (2021) (31)
- Corrigendum: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [Ann Oncol, 27(Suppl 5), (2016), (v83-v90)] doi: 10.1093/annonc/mdw400 (2017) (31)
- Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL) (2004) (30)
- Distribution of the cytogenetic abnormality +i(3)(q10) in persistent polyclonal B‐cell lymphocytosis: a FICTION study in three cases (1997) (30)
- A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication. (2016) (30)
- CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma (2011) (30)
- EPICC study: evaluation of pharmaceutical intervention in cancer care (2015) (30)
- Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma (2020) (30)
- HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. (2018) (30)
- Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. (2017) (30)
- High CD 34 1 Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation (1998) (29)
- Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study (2016) (29)
- Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study (2019) (29)
- A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. (2021) (29)
- Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase (2014) (28)
- Human γδ T Cells Express a Higher TCR/CD3 Complex Density Than αβ T Cells (2001) (28)
- RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA (2008) (28)
- The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. (2010) (28)
- Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma (2019) (28)
- Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials. (2021) (27)
- In non‐follicular lymphoproliferative disorders, IGH/BCL2‐fusion is not restricted to chronic lymphocytic leukaemia (2012) (27)
- Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma (2002) (27)
- Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas (2000) (27)
- Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin (2007) (26)
- Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma (2015) (26)
- Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial (2019) (26)
- A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas. (1998) (26)
- Mutational Landscape of Grey Zone Lymphoma. (2019) (25)
- Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (2016) (25)
- Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis (2014) (25)
- On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors (2019) (25)
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. (2015) (25)
- Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. (2019) (25)
- Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from non-Hodgkin's lymphoma patients. (2001) (25)
- Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial (2020) (25)
- Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France (2004) (25)
- Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93 (1997) (24)
- POEMS syndrome, arterial thrombosis and thrombocythaemia (1996) (24)
- Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes (2019) (24)
- Targeting netrin‐1/DCC interaction in diffuse large B‐cell and mantle cell lymphomas (2016) (24)
- ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. (2017) (24)
- Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. (2004) (24)
- Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles (2019) (24)
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial (2019) (24)
- Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines (2015) (24)
- A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials (2016) (24)
- GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. (2015) (23)
- Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies. (2004) (23)
- Comparative toxicities of 3 platinum‐containing chemotherapy regimens in relapsed/refractory lymphoma patients (2017) (23)
- A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL (2014) (23)
- Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. (2021) (23)
- Current and future management of follicular lymphoma (2012) (23)
- Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR sponsored LMBA02, NCT00180882) (2012) (23)
- Lenalidomide is safe and active in Waldenström macroglobulinemia (2015) (23)
- Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non‐Hodgkin's lymphoma (2007) (23)
- A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. (2020) (23)
- Gene expression profiling of gray zone lymphoma. (2020) (22)
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. (2004) (22)
- 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients (2010) (22)
- Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant? (2016) (22)
- Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma (2007) (22)
- Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. (2017) (22)
- Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. (2015) (22)
- Treatment approach to newly diagnosed diffuse large B-cell lymphoma. (2015) (22)
- T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy? (2008) (22)
- Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). (2014) (22)
- A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. (2012) (22)
- Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. (2021) (22)
- High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia (2017) (22)
- Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma (1998) (22)
- Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL) (2010) (22)
- Sequential combination of high dose methotrexate and l-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm (2012) (22)
- Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. (2014) (22)
- Distinct chromosome 3 abnormalities in persistent polyclonal B‐cell lymphocytosis (1999) (21)
- Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. (1997) (21)
- Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind (2018) (21)
- Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL (2010) (21)
- An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. (2018) (21)
- Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma (2008) (21)
- CD1d-restricted peripheral T cell lymphoma in mice and humans (2016) (21)
- The Biology of Aging and Lymphoma: a Complex Interplay (2015) (20)
- Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study (2011) (20)
- Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. (2021) (20)
- A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (2012) (20)
- Hairy cell leukaemia‐variant and splenic red pulp lymphoma: a single entity? (2010) (20)
- A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B‐cells (2016) (20)
- Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? (2018) (20)
- Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment. (2008) (20)
- Metagenomic Next-Generation Sequencing Reveals Individual Composition and Dynamics of Anelloviruses during Autologous Stem Cell Transplant Recipient Management (2018) (20)
- Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study (2010) (20)
- Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed? (2011) (20)
- Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (2019) (20)
- Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) (2013) (19)
- Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. (2007) (19)
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up (2007) (19)
- Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. (2020) (19)
- Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. (2018) (19)
- Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma (2017) (19)
- Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial. (2009) (19)
- Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma? (2014) (19)
- BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial (2017) (19)
- The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies (2018) (19)
- Prevalence of Anticentromere F Protein Autoantibodies in 347 Patients with Non‐Hodgkin's Lymphoma (2005) (18)
- First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa (2016) (18)
- Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review (2017) (18)
- Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) (2013) (18)
- Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies (2018) (18)
- Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. (2019) (18)
- Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial (2017) (18)
- Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. (2013) (18)
- Successful pregnancies in patients with BCR‐ABL‐positive leukemias treated with interferon‐alpha therapy during the tyrosine kinase inhibitors era (2018) (17)
- An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL) (2014) (17)
- Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience (2016) (17)
- BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab (2017) (17)
- Multifocal progressive leukoencephalopathy occurring after refractory anemia and multiple infectious disorders consecutive to severe lymphopenia (2002) (17)
- Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. (2022) (17)
- Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. (2019) (17)
- 10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma. (2009) (17)
- Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience (2019) (17)
- Skin lesions in malignancy. Case 3. Yellow nail syndrome in non-Hodgkin's lymphoma. (2001) (17)
- Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B‐cell non‐Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306) (2019) (17)
- S-phase lengthening induced by p16INK4a overexpression in malignant cells with wild-type pRb and p53 (2010) (16)
- A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders (2014) (16)
- INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (2019) (16)
- Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (2018) (16)
- Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma. (2020) (16)
- FLT3‐TKD Mutations Associated With NPM1 Mutations Define a Favorable‐risk Group in Patients With Acute Myeloid Leukemia (2018) (16)
- Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. (2018) (16)
- Lentiviral vectors and transduction of human cancer B cells. (2010) (16)
- Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy (2021) (16)
- Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients. (2019) (16)
- A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL). (2015) (16)
- Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies (2016) (16)
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel (2019) (16)
- Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. (2021) (16)
- Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials (2016) (16)
- A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma (2014) (16)
- Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. (1999) (16)
- Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL (2018) (16)
- Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years. (2004) (16)
- Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma (2021) (16)
- RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (2020) (15)
- Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review (2019) (15)
- Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999), (2011) (15)
- RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. (2018) (15)
- Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) (2007) (15)
- Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension (2020) (15)
- Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution (1999) (15)
- A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma (2013) (15)
- Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay (2017) (15)
- Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999) (2011) (15)
- Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell lymphoma. (2004) (15)
- Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma (2016) (15)
- Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B‐cell lymphoma, a clinico‐pathological series of 25 cases (2020) (15)
- Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation (2018) (15)
- Cytogenetic and Molecular Analysis of 12 Cases of Primary Cutaneous Marginal Zone Lymphomas (2006) (15)
- Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial. (2016) (15)
- Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era (2015) (15)
- Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study (2019) (15)
- Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial (2017) (14)
- Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study. (2018) (14)
- POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL (2019) (14)
- Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma (2021) (14)
- The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia. (2016) (14)
- Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review (2017) (14)
- Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) (2019) (14)
- Administration of anticancer drugs: exposure in hospital nurses. (2014) (14)
- CD20‐TCB (RG6026), A NOVEL “2:1” FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA (2019) (14)
- Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies (2017) (14)
- The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL) (2014) (14)
- Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study (2018) (14)
- POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. (2019) (13)
- A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts (2018) (13)
- Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma. (2005) (13)
- Comparison of LIC Obtained from Biopsy, BLS and R 2 -MRI in Iron Overloaded Patients with β-Thalassemia, Treated with Deferasirox (Exjade®, ICL670). (2005) (13)
- Human gammadelta T cells express a higher TCR/CD3 complex density than alphabeta T cells. (2001) (13)
- Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding (2017) (13)
- Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (2017) (13)
- Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis (2002) (13)
- Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. (2020) (13)
- Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies (2010) (13)
- Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study (2016) (13)
- One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy (2018) (13)
- Biosimilar monoclonal antibodies in lymphoma: a critical appraisal (2015) (13)
- Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas (2020) (12)
- Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. (2011) (12)
- SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma (2017) (12)
- Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). (2014) (12)
- Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B‐cell lymphoma (2008) (12)
- Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR) (2014) (12)
- Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. (2014) (12)
- FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts (2017) (12)
- Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells (2021) (12)
- Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study. (2013) (12)
- Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases (2013) (12)
- Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study (2016) (12)
- Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma (2015) (12)
- Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5 (2020) (12)
- EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. (2021) (12)
- Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (2015) (11)
- Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma. (2004) (11)
- Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma (2020) (11)
- RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma (2021) (11)
- Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). (2016) (11)
- Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia (2020) (11)
- Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma (2020) (11)
- Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. (2016) (11)
- Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas (2017) (11)
- Recurrent cerebral venous thrombosis revealing paraneoplastic angiitis in Hodgkin’s lymphoma (2008) (11)
- Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? (2017) (11)
- A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia. (2014) (11)
- THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE (2017) (11)
- Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study (2013) (10)
- Prognostic systems for lymphomas. (2008) (10)
- Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients. (1994) (10)
- Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma (2020) (10)
- Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL). (2010) (10)
- Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience (2017) (10)
- Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma. (2008) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Intensifi ed chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diff use large B-cell lymphoma ( LNH 032 B ) : an open-label randomised phase 3 trial (2011) (10)
- Inherited cytokine response and risk of lymphoma. (2006) (10)
- Sever immune thombocytopenic purpura and haemolytic anaemia in a hairy‐cell leukaemia patient (1995) (10)
- Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia (2015) (10)
- Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy (2015) (10)
- What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies (2018) (10)
- The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas. (2007) (10)
- Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy. (2021) (9)
- Obinutuzumab for chronic lymphocytic leukemia (2014) (9)
- PET-CT and diagnostic CT: the synergy of metabolic and morphological data in onco-haematology. (2014) (9)
- Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma. (2016) (9)
- Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo. (2016) (9)
- Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. (2012) (9)
- Histologic transformation in follicular lymphoma. (1998) (9)
- EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL (2019) (9)
- Cost Effectiveness Analysis of Rituximab Maintenance In Patients with Untreated High Tumour Burden Follicular Lymphoma After Response to Immunochemotherapy: A UK National Healthcare Services Perspective. (2010) (9)
- First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. (2013) (9)
- Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000) (2011) (9)
- Identification of two lymphotoxin beta isoforms expressed in human lymphoid cell lines and non-Hodgkin's lymphomas. (1997) (9)
- Optimizing CAR T cell therapy in lymphoma (2021) (9)
- Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): NHL‐133 (2018) (9)
- Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study (2021) (9)
- Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy. (2010) (9)
- A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). (2013) (9)
- Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management (2014) (9)
- Pregnancy and multiple myeloma are not antinomic (2013) (9)
- Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia (2019) (9)
- Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study. (2015) (9)
- Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?. (2007) (9)
- Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis. (2019) (9)
- Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. (2008) (9)
- Improving Cancer Patient Care with Combined Medication Error Reviews and Morbidity and Mortality Conferences (2014) (8)
- Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients. (2001) (8)
- Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (2020) (8)
- Early‐onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure (2019) (8)
- CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS (2019) (8)
- Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (2014) (8)
- Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration (1991) (8)
- Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study (2010) (8)
- Idelalisib immune-related toxicity is associated with improved treatment response (2021) (8)
- Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2020) (8)
- VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients (2019) (8)
- Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL) (2015) (8)
- for the Groupe d'Etude des Lymphomes de l'Adulte (GELA) (2013) (8)
- Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL). (2014) (8)
- Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24). (2021) (8)
- Acute myeloid leukemia in the elderly (age 70 yr or older): long‐term survivors (2017) (8)
- Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2021) (8)
- A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies (2014) (8)
- Chemotherapy-free treatment in patients with follicular lymphoma (2015) (8)
- Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial (2017) (8)
- The role of tazemetostat in relapsed/refractory follicular lymphoma (2021) (8)
- The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate (2009) (8)
- Prospects in the management of patients with follicular lymphoma beyond first-line therapy. (2022) (7)
- Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study. (2007) (7)
- The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. (2015) (7)
- R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B (2011) (7)
- Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study. (2015) (7)
- A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma. (2014) (7)
- Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies (2016) (7)
- Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 (2019) (7)
- Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) (2019) (7)
- A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY (2017) (7)
- Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205) (2020) (7)
- CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment (2016) (7)
- Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis. (2008) (7)
- Introduction to a review series: the 2016 revision of the WHO classi fi cation of tumors of hematopoietic and lymphoid tissues (2016) (7)
- Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study (2021) (7)
- Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature (2017) (7)
- Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA) (2015) (7)
- Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa (2019) (7)
- BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. (2020) (7)
- Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas (2021) (7)
- Efficacy and safety of revaccination against tetanus, diphtheria, Haemophilus influenzae type b and hepatitis B virus in a prospective cohort of adult recipients of allogeneic hematopoietic stem cell transplantation. (2020) (7)
- Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (2017) (7)
- Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study (2016) (7)
- Array‐CGH predicts prognosis in plasma cell post‐transplantation lymphoproliferative disorders (2017) (7)
- Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1 (2021) (7)
- Is there a role for bortezomib combinations in the management of patients with follicular lymphoma? (2011) (7)
- R-DHA-Oxaliplatin before Autologous Stem Cell Transplantation Prolongs PFS and OS As Compared to R-DHA-Carboplatin and R-DHA-Cisplatin in Patients with Mantle Cell Lymphoma, a Subgroup Analysis of the LyMa Trial (2017) (7)
- R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study. (2012) (7)
- Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sézary syndrome (2007) (7)
- Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network (2021) (7)
- Research protocol on early palliative care in patients with acute leukaemia after one relapse (2017) (7)
- The detection of bone marrow involvement in small-cell lung cancer using magnetic resonance imaging. (1988) (7)
- Biomarkers and prognosis in malignant lymphomas. (2009) (6)
- Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. (2022) (6)
- Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT). (2007) (6)
- Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients (2015) (6)
- Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study (2020) (6)
- Resources-Stratified Guidelines for Classical Hodgkin Lymphoma (2020) (6)
- Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts (2022) (6)
- High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B (2021) (6)
- Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy. (2008) (6)
- Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation (2018) (6)
- Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma (2021) (6)
- Detection of Leukemic Phase in Patients with Follicular Lymphoma At Diagnosis: A Rare Event Associated with Poor Prognosis (2012) (6)
- Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS) (2015) (6)
- Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials (2013) (6)
- Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. (2021) (6)
- REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM (2019) (6)
- A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). (2014) (6)
- Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999) (2010) (6)
- Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients? (2021) (6)
- A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort (2021) (6)
- Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA. (2020) (6)
- Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring (2021) (6)
- Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease (2018) (6)
- A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. (2020) (6)
- AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma. (2013) (6)
- Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. (2007) (6)
- An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma. (2013) (6)
- CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas (2021) (6)
- Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment (2017) (6)
- Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study (2010) (6)
- ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL) (2019) (5)
- Modulation of costimulatory molecules on follicular lymphoma cells by TNF and CD40. (1999) (5)
- PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND) (2019) (5)
- FDG PET/CT Findings in Abdominal Fat Necrosis After Treatment for Lymphoma. (2016) (5)
- Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study (2022) (5)
- Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia (2019) (5)
- Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program. (2021) (5)
- The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (2021) (5)
- Definition of a minimal genes set for mature lymphoid blood diseases (2018) (5)
- Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (2018) (5)
- The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL. (2014) (5)
- Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial (2013) (5)
- A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA (2017) (5)
- The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell. (2006) (5)
- MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte (2012) (5)
- Mutational Landscape of Grey Zone Lymphoma. (2019) (5)
- A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial (2019) (5)
- Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies (2016) (5)
- Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial (2018) (5)
- Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma. (2007) (5)
- The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR) (2018) (5)
- A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma (2016) (5)
- L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. (2017) (5)
- The Poor Prognosis Value of High Intra-Tumoral Macrophages Counts in Follicular Lymphoma Patients Requires Selection of Appropriate Cut-Off and Can Be Circumvented by Rituximab Therapy. (2006) (5)
- A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas. (2010) (5)
- Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib (2017) (5)
- Case report: Purulent transformation of granulocytic sarcoma (2018) (5)
- Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification (2017) (5)
- Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma (2017) (5)
- Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma. (2017) (4)
- Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study (2018) (4)
- Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients (2013) (4)
- Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma (2016) (4)
- Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of 175 Patients Treated in the GELA/GOELAMS FL 2000 Study (2008) (4)
- Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS) (2020) (4)
- Characterization of germinal center dendritic cells in follicular lymphoma. (1999) (4)
- Refractory diffuse large B‐cell lymphoma after first‐line immuno‐CT: Treatment options and outcomes (2018) (4)
- A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors (2000) (4)
- R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET (2020) (4)
- Comparison Study for Genotyping of a Single-Nucleotide Polymorphism in the Tumor Necrosis Factor Promoter Gene (2002) (4)
- Management of transaminase elevations in patients receiving idelalisib. (2016) (4)
- Abstract LB-272: Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma (2014) (4)
- Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC) (2019) (4)
- HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY (2019) (4)
- Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study (2016) (4)
- Rituximab maintenance therapy for follicular lymphoma – Authors' reply (2011) (4)
- [Marginal zone B-cell lymphoma affecting the skin: histological and phenotypic study of 49 cases]. (2008) (4)
- Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial (2011) (4)
- Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma (2015) (4)
- Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV (2022) (4)
- Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19 (2019) (4)
- Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia (2020) (4)
- Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study (2017) (4)
- Prognostic Impact Of Somatic NOTCH2 Mutation In Splenic Marginal Zone Lymphoma (2013) (4)
- Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study (2018) (4)
- Cat-Scratch Disease: A Pitfall for Lymphoma Evaluation by FDG-PET/CT. (2017) (4)
- Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study (2015) (4)
- Cytogenetic and molecular delineation of a region of chromosome 3 q commonly gained in marginal zone B-cell lymphoma (2002) (4)
- Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study (2020) (4)
- Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019) (4)
- Long Term Follow-up of the GELF86 French and Belgian Trials : Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission. (2008) (4)
- IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era (2013) (4)
- Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) (2017) (4)
- Genetically Determined Height and Risk of Non-hodgkin Lymphoma (2020) (4)
- Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma. (2008) (4)
- Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial (2021) (4)
- Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. (2021) (4)
- Desynchronization of the Germinal Center Dynamics and Remodeling of the Tumor Microenvironment Characterize KMT2D-Driven Lymphomagenesis (2018) (4)
- Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma (2020) (4)
- [Thymic tumours, autoimmune neutropaenia and autoimmune haemolytic anaemia]. (2008) (3)
- Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule. (2004) (3)
- [Pathological and clinical correlations in primary cutaneous B-cell lymphomas: a series of 44 cases]. (2005) (3)
- Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study (2016) (3)
- How do I sequence therapy for follicular lymphoma? (2020) (3)
- Towards new prognostic factors in diffuse large cell non-Hodgkin's lymphoma. (1996) (3)
- High circulating tumor necrosis factor levels correlate with increased evels of soluble CD14 in patients with non-Hodgkin's lymphoma. (2001) (3)
- Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. (2021) (3)
- CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS (2017) (3)
- Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. (2021) (3)
- Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigentic reprogramming. (2021) (3)
- What is the best first-line treatment strategy for patients with indolent lymphomas? (2012) (3)
- S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM (2019) (3)
- Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma (2020) (3)
- Tumoral Maximum Standardized Uptake Value > 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome (2014) (3)
- Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. (2017) (3)
- Ibrutinib-Induced Lymphocytosis: Cytological Features (2016) (3)
- Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5. (2021) (3)
- Analysis of IgVH, BCL-6, PIM, RHO/TTF and PAX5 Mutational Status in Splenic and Nodal Marginal Zone B Cell Lymphoma Suggests a Particular B Cell Origin. (2005) (3)
- Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients (2016) (3)
- Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas (2011) (3)
- Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies. (2014) (3)
- Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study (2019) (3)
- Chronic Borrelia burgdorferi infection triggers NKT lymphomagenesis. (2018) (3)
- Hepatic angiosarcoma in a patient with essential thrombocythaemia and Budd-Chiari syndrome. (1995) (3)
- INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL (2019) (3)
- Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. (2021) (3)
- Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial (2019) (3)
- SEQUENTIAL TREATMENT WITH RITUXIMAB AND CHOP CHEMOTHERAPY IN B-CELL PTLD – WILL RISK STRATIFIED SEQUENTIAL TREATMENT BECOME THE NEW STANDARD IN THERAPY?: 292 (2008) (3)
- Drug cost savings in phase III hematological oncology clinical trials in a university hospital (2020) (3)
- Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials (2017) (3)
- Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop (2016) (3)
- Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice. (2021) (3)
- Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a ‘Real-Life’ Study (2020) (3)
- IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY (2019) (3)
- [Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. (2017) (3)
- A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX). (2018) (3)
- Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance (2021) (3)
- Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma (2018) (3)
- Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study (2019) (3)
- Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas (2017) (3)
- Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project (2020) (3)
- Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries (2018) (3)
- Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL). (2019) (3)
- Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. (2005) (3)
- Real‐life targeted next‐generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network (2021) (3)
- Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL) (2002) (3)
- Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets (2016) (3)
- Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma (iNHL) in idelalisib (IDELA) trials. (2015) (3)
- Metagenomic Investigation of Torque Teno Mini Virus-SH in Hematological Patients (2019) (3)
- Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities. (2022) (3)
- [Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]. (2017) (3)
- Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). (2021) (3)
- Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (2022) (2)
- Maintenance therapy in follicular lymphoma (2011) (2)
- Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study (2018) (2)
- Allogeneic anti-CD19 CAR T cells: new perspectives in the treatment of B-cell malignancies that progress after allogeneic stem cell transplantation? (2016) (2)
- A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists (2015) (2)
- A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study (2013) (2)
- Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response (2020) (2)
- Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1 (2022) (2)
- Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies (2015) (2)
- Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (2019) (2)
- Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440) (2020) (2)
- PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers (2020) (2)
- PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA (2017) (2)
- Diffuse large B cell lymphoma in adults (2010) (2)
- Human germinal center transcriptional programs are de-synchronized in B cell lymphoma (2018) (2)
- Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC‐based first‐line treatment: Retrospective observations from the FILO group (2018) (2)
- Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab. (2005) (2)
- Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study (2016) (2)
- Predictive gene-expression score for follicular lymphoma - Authors' reply. (2018) (2)
- ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study (2021) (2)
- Prognosis value of baseline total metabolic tumor volume (TMTV) in advanced Hodgkin lymphoma (HL) : Ancillary study of AHL2011 LYSA trial (2016) (2)
- BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) (2019) (2)
- Pattern of infections observed during the maintenance phase in the PRIMA study (2011) (2)
- Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma (2022) (2)
- A New Immunohistochemical Algorithm Using Four Antibodies Has a High Concordance with Gene Expression Profiling Defined ABC and GCB Diffuse Large B-Cell Lymphoma (2017) (2)
- Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study (2021) (2)
- Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. (2019) (2)
- Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR 3 A and FCGR 2 A polymorphisms (2012) (2)
- Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study (2018) (2)
- Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study (2011) (2)
- Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. (2021) (2)
- A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy (2018) (2)
- Asparagine Synthetase Expression and L-Asparaginase Sensitivity in Aggressive Lymphomas (2014) (2)
- Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy (2020) (2)
- Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000) (2013) (2)
- Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. (2019) (2)
- Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma (2013) (2)
- Session 8: pathology and clinicopathological correlations 077 THE RELIABILITY OF IMMUNOHISTOCHEMICAL ANALYSIS OF TUMOR MICROENVIRONMENT IN FOLLICULAR LYMPHOMA; A VALIDATION STUDY FROM THE LUNENBURG LYMPHOMA BIOMARKER CONSORTIUM (LLBC) (2011) (2)
- Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study (2020) (2)
- A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL) (2022) (2)
- Reply to H.J.A. Adams et al and E. Laffon et al. (2017) (2)
- A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL) (2021) (2)
- Pediatric ALL-like Therapy in Adults with T-Cell Lymphoblastic Lymphoma: Results of the Graall-Lysa LL03 Study (2014) (2)
- [News in therapeutic management of chronic lymphoid leukemia]. (2005) (2)
- Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies (2021) (2)
- Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia (2016) (2)
- Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy (2017) (2)
- Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATETM and RESONATE-2TM with the French Lyon-Sud Database (2016) (2)
- Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma (2021) (2)
- Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study. (2018) (2)
- Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients (2012) (2)
- [The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas]. (2005) (2)
- Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) (2018) (2)
- Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia. (2017) (2)
- Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting. (2020) (2)
- [The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas]. (2005) (2)
- CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (2021) (2)
- Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy (2004) (2)
- Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response (2005) (2)
- High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study (2014) (2)
- Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects (2020) (2)
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical) (2022) (2)
- Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies (2021) (2)
- Late intensification is superior to early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma. A randomized study from the GELA: LNH RP93. (1997) (2)
- Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database (2018) (2)
- ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST‐LINE BENDAMUSTINE + RITUXIMAB OR R‐CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL‐WORLD COHORT (2021) (2)
- Long Term Follow-Up Shows No Clinical Benefit for CD34+ Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study. (2004) (2)
- Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. (2022) (2)
- S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL (2019) (2)
- Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. (2017) (2)
- Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma (2022) (2)
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical) (2022) (2)
- Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study. (2016) (2)
- Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial. (2021) (2)
- [Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. (2017) (2)
- ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2020) (2)
- Rituximab maintenance after autologous stem‐cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group (2017) (2)
- Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant (2020) (2)
- RISK STRATIFIED SEQUENTIAL TREATMENT WITH RITUXIMAB AND CHOP CHEMOTHERAPY IN B-CELL PTLD - DEFINING A NEW STANDARD OF CARE: RESULTS FROM A PROSPECTIVE INTERNATIONAL MULTICENTER TRIAL: 1322 (2010) (2)
- Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience (2022) (1)
- XVI meeting of the European Association for Haematopathology 2012 Abstracts (2012) (1)
- Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma (2016) (1)
- Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular Therapy Study (2016) (1)
- Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program (2018) (1)
- Rituximab/Chemotherapy Induction Treatment Followed by High-Dose Therapy and Autologous Transplantation in Patients with Mantle Cell Lymphoma. (2004) (1)
- PD‐1 BLOCKADE IN A FRENCH SERIES OF 13 RELAPSED / REFRACTORY NK/T‐CELL LYMPHOMA PATIENTS (2019) (1)
- TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma (2021) (1)
- Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT (2017) (1)
- 53TiPPembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study (2016) (1)
- Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma (2021) (1)
- Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) (2017) (1)
- Final Results of a Phase I Study of the Anti-CD79b Antibody-Drug Conjugate DCDS4501A (Polatuzumab Vedotin) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 4400 (2013) (1)
- Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study (2008) (1)
- A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019) (1)
- Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing (2022) (1)
- CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY (2021) (1)
- Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant? (2016) (1)
- New Treatment Options in Advanced Stage Follicular Lymphoma (2018) (1)
- EARLY Interim FDG-PET Scan in Localised Hodgkin Lymphoma: Evaluation of Practice in 5 French Centers (2008) (1)
- Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma (2019) (1)
- IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL) (2020) (1)
- Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440) (2018) (1)
- Long term efficacy of rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Update of the multicenter, open label, phase II trial (M39037 trial) (2006) (1)
- Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma (2022) (1)
- The use of tafasitamab in diffuse large B-cell lymphoma (2021) (1)
- A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study (2019) (1)
- Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study (2014) (1)
- A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs). (2016) (1)
- Non-Hodgkin's lymphoma Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma (2004) (1)
- Anti-Leukemic Activity of a Novel Pegylated Recombinant Erwinia Chrysanthemi-Derived L-Asparaginase On Lymphoid Cell Lines and Leukemia-Bearing Mouse Models. (2012) (1)
- Phase Ib study of plitidepsin (APL) with gemcitabine (GEM) in refractory solid tumors and lymphoma patients. (2012) (1)
- Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) (2021) (1)
- Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2016) (1)
- Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma: Vitamin D insufficiency and CAR-T in LBCL. (2022) (1)
- Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2TM and RESONATETM with RW Databases (2018) (1)
- Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma (2020) (1)
- Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma (2022) (1)
- Early Stage Follicular Lymphoma: Is There a Clinical Impact of First Line Treatment? (2012) (1)
- outcome of diffuse large B-cell lymphoma The interleukin-10 gene promoter polymorphisms influence the clinical (2013) (1)
- Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma (2022) (1)
- CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST‐LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE. (2017) (1)
- Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile. (2020) (1)
- OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY (2019) (1)
- Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study (2020) (1)
- Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study (2015) (1)
- Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region. (2019) (1)
- Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study (2015) (1)
- The EHA Research Roadmap: Malignant Lymphoid Diseases (2022) (1)
- Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study (2020) (1)
- Prognostic Value of P53 and Myc Protein Expression in Follicular Lymphomas in the PRIMA Trial in the Lysa Group (2017) (1)
- Single nucleotide polymorphisms in ABCB 1 and CBR 1 can predict toxicity to R-CHOP type regimens in patients with diffuse non Hodgkin lymphoma by (2015) (1)
- Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study (2020) (1)
- Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat (2021) (1)
- Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients (2021) (1)
- [Clinical research activity of the French cancer cooperative network: Overview and perspectives]. (2017) (1)
- Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies (2016) (1)
- Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma (2017) (1)
- Evaluation of Participation and Recruitment Bias in a Prospective Real-Life Multicentric Cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for Newly Diagnosed Lymphoma Patients over One Year in a Hematology Department of Teaching Hospital (2022) (1)
- Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study (2007) (1)
- Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa (2015) (1)
- Mechanisms of Telomere Maintenance Dysfunction in B-Chronic Lymphocytic Leukemia Through CpG Island Methylation (2012) (1)
- PRELIMINARY RESULTS OF A PHASE 1B STUDY OF TIRABRUTINIB (GS‐4059/ONO‐4059) IN COMBINATION WITH ENTOSPLETINIB IN PATIENTS WITH B‐CELL MALIGNANCIES (2017) (1)
- Maintenance Alemtuzumab in Refractory B-Cell Chronic Lymphocytic Leukemia Patients: Updated Data. (2005) (1)
- Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era (2017) (1)
- High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial (2018) (1)
- Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation. (2022) (1)
- Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study (2013) (1)
- Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. (2022) (1)
- [Lymphomas. How to best approach the 12,000 new cases every year of this disease, varied in presentation and evolution?]. (2010) (1)
- Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. (2017) (1)
- Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study (2021) (1)
- A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group (2019) (1)
- Isolated hepatosplenic sarcoidosis: A pitfall for lymphoma evaluation by 18F-FDG PET/CT. (2017) (1)
- Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program (2022) (1)
- Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL (2015) (1)
- CNS prophylaxis in diffuse large B-cell lymphoma – Authors' reply (2012) (1)
- Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) (2018) (1)
- Complete Remission After First-Line Radio Plus Chemotherapy Is Enough to Improve Survival in Extra Nodal NK/T Cell lymphoma (2011) (1)
- L‐MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R‐R DLBCL) – A SINGLE‐ARM PHASE II STUDY (2017) (1)
- Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England (2022) (1)
- [Follicular lymphoma: An update]. (2019) (1)
- [Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. (2017) (0)
- Inhibition of CD 10 / neutral endopeptidase 24 . 11 promotes B-cell reconstitution and maturation in vivo ( common acute lymphoblastic leukemia antigen / lymphoid progenitors / differentiation / cell surface enzyme ) (2005) (0)
- [Evans syndrome, pseudotumoral lymphoid hyperplasia and deficit of IgA-IgG2-IgG4]. (1995) (0)
- Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma (2018) (0)
- l'Adulte (GELA) non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de Prognostic significance of bcl-2 protein expression in aggressive (2002) (0)
- Early Human Herpes Virus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Observational Study of 196 Patients (VIRAUTO 6) (2016) (0)
- Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma. (2005) (0)
- Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (2012) (0)
- Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma (2023) (0)
- Is anemia an important prognostic factor in non-Hodgkins lymphoma patients? (1996) (0)
- Impact of Rituximab on Peripheral Blood Stem Cell Mobilization and Collection Following ACVBP Regimen in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Large Cohort of Patients from Two Prospective GELA Trials. (2008) (0)
- Targeting netrin-1 / DCC interaction in Diffuse Large-B and Mantle Cell Lymphoma (2015) (0)
- HUMAN LEUKOCYTE ANTIGENS CLASS II (HLA DRB1) AND TUMOR NECROSIS FACTOR GENETIC POLYMORPHISMS ARE INDEPENDENT PREDICTORS OF NON-HODGKIN'S LYMPHOMA OUTCOME Short title: HLA DRB1/TNF polymorphisms and lymphoma outcome (2002) (0)
- Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial (2018) (0)
- Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study (2017) (0)
- SAFETY AND EFFICACY OF ATEZOLIZUMAB, OBINUTUZUMAB AND VENETOCLAX COMBINATION FOR RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMAS: RESULTS FROM THE SAFETY‐RUN OF A LYSA STUDY (2019) (0)
- Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T‐cell lymphoma: A French retrospective study (2023) (0)
- Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma (2018) (0)
- Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma (2020) (0)
- Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study (2015) (0)
- Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome. (2009) (0)
- PB1893 NON-INTERVENTIONAL RETROSPECTIVE MULTICENTER STUDY EVALUATING REAL WORD IDELALISIB USE IN CLL AND INHL PATIENTS ENROLLED IN THE FRENCH EARLY ACCESS PROGRAM (EAP) (2019) (0)
- Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience (2021) (0)
- Identification of Previously Unrecognized CD1d-Restricted Peripheral T Cell Lymphomas (PTCLs) in Mouse and Human Reveals Blocking Anti-CD1d Monoclonal Antibodies As a New Therapeutic Possibility in PTCLs (2014) (0)
- Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL) (2014) (0)
- Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) (2017) (0)
- THE CLINICAL COURSE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META‐DATA FROM 13 FIRST‐LINE RANDOMIZED TRIALS (2019) (0)
- [Update on lymphomas: 1997, a profitable year]. (1998) (0)
- Development of model for analysing respective collections of intended hematopoietic stem cells and harvests of unintended mature cells in apheresis for autologous hematopoietic stem cell collection. (2014) (0)
- Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma (2018) (0)
- Highlights in relapsed/refractory follicular lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. (2021) (0)
- and FCGR3A chemoimmunotherapy in the PRIMA study is not affected by Clinical outcome of patients with follicular lymphoma receiving (2014) (0)
- presentation and outcome in 124 patients Non-MALT marginal zone B-cell lymphomas: a description of clinical (2013) (0)
- Comparison of Clinical Characteristics, Plasma Cytokine Signature, Cytokine Gene Polymorphisms and Outcome Between EBV Positive and Negative Hodgkin Lymphoma: a Study of the Groupe Des Lymphomes De l'Adulte (GELA) (2010) (0)
- COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B‐CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT‐LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL (2019) (0)
- lymphoma patients: results of the GELA-GOELAMS FL2000 study Rituximab combined with chemotherapy and interferon in follicular (2013) (0)
- Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study (2020) (0)
- REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE (2019) (0)
- Treatment approaches to asymptomatic follicular lymphoma (2013) (0)
- ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2020) (0)
- PF296 UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS (2019) (0)
- The Biologic Interconnections Between Aging and Lymphoma (2020) (0)
- Identification of a novel major brekpoint region (MBR) on the MALT1 gene from t(14;18)(q32;q21)/IGH-MALT1-positive MALT lymphomas (2010) (0)
- O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND) (2021) (0)
- Tumor necrosis factor and lymphotoxin ligand-receptor system in lymphoproliferative disorders. (1995) (0)
- Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1-2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials (2018) (0)
- INFECTIONS FOLLOWING PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION. AUTHORS' REPLY (1999) (0)
- Authors' Reply. (2018) (0)
- CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas. (2017) (0)
- Long‐term outcomes of patients with limited‐stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era (2022) (0)
- [Treatment of aggressive primary lymphomas of the digestive system by intensive chemotherapy. Experience of the Study Group on Lymphomas in Adults with the LNH-84 protocol]. (1992) (0)
- Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study (2023) (0)
- Circulating t(14;18)+ Cells As Predictive Markers Of Follicular Lymphoma Development (2013) (0)
- with classical Hodgkin lymphoma from that of other diffuse large B-cell lymphomas and shares features The molecular signature of mediastinal large B-cell lymphoma differs (2013) (0)
- Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL) (2021) (0)
- Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies (2012) (0)
- t(14;18) with BCL2-IGH rearrangement (2003) (0)
- Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis (2016) (0)
- Abstract 221: Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma (2018) (0)
- A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies. (2018) (0)
- Hurdles and Unmet Needs in the Management of Indolent Non-Hodgkin Lymphoma (2017) (0)
- Vitamin D Deficiency Is Associated with Inferior Clinical Outcomes in Patients with Large B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy (2022) (0)
- study from the GELA patients with advanced follicular lymphoma: the GELF-94 randomized high-dose therapy with autologous stem cell transplantation in untreated Standard chemotherapy with interferon compared to CHOP followed by (2013) (0)
- Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2021) (0)
- Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing (2015) (0)
- Abstract 4055: Non-canonical telomere maintenance mechanism in B-cell chronic lymphocytic leukemia. (2013) (0)
- ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III (2022) (0)
- Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience (2021) (0)
- Long-Term Remission (>3 years) after Rituximab Monotherapy Used for Patients with Relapsed Indolent Non-Hodgkin Lymphomas (NHL) (2014) (0)
- Expression of a Dysfunctional Activation Induced Cytidine Deaminase Is Correlated with Disease Progression in Splenic Marginal Zone Lymphoma. (2012) (0)
- Tumor-infiltrating T lymphocytes and morphogenesis of follicular lymphoma-reply. (2017) (0)
- Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial (2019) (0)
- Malignant LymphomasResearch Paper (2005) (0)
- [Clinical study of 12 cases of malignant non-Hodgkin's lymphoma of the orbital region]. (1993) (0)
- Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study (2014) (0)
- Is Conventional Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) an Optimal Long-Term Strategy for Non Hodgkin Lymphomas: A Retrospective Study from 1987 to 2004. (2004) (0)
- LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY (2017) (0)
- Peripheral Blood Progenitor Cell Transplantation High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous (2013) (0)
- ABERRANT SOMATIC HYPERMUTATION IN PRIMARY MED- IASTINAL LARGE B-CELL LYMPHOMA CONTAINS NUCLEAR EXPORT SIGNALS AND REGU- LATES CYTOPLASMIC LOCALIZATION OF BCL10 (2005) (0)
- A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients (2014) (0)
- ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years. (2022) (0)
- Reappraisal Of The p16INK4A/Prb Pathway and Telomerase Activity, Markers Of Cell Activation and Aging, In Adult Acute Lymphoblastic Leukemia: A Graall Study (2013) (0)
- TUMOR GENOMIC COPY NUMBER ABNORMALITIES ANALYZED BY HIGH RESOLUTION SNP ARRAY IMPACT OUTCOME OF PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS ON 68 PATIENTS (2017) (0)
- Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d’Etudes des Lymphomes de l’Adulte (GELA) (2008) (0)
- Bone-marrow Transplantation Prolongs Survival After Relapse in Lymphoma Patients - Long-term Follow-up (1993) (0)
- CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD (2019) (0)
- Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Juliet Trial (2021) (0)
- Mir-21 Is Over Expressed in Aggressive SMZL (2008) (0)
- Abstract 5186: Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial (2022) (0)
- Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma (2020) (0)
- Contribution of bio-informatics analysis in non-Hodgkin’s lymphoma (2005) (0)
- Abstract 4921: Population pharmacokinetic modeling of ibrutinib administered in patients with relapsed or refractory B cell malignancies eligible for autologous stem cell transplantation (2018) (0)
- correlates with shelterin dysregulation Telomeric damage in early stage of chronic lymphocytic leukemia (2013) (0)
- Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). (2022) (0)
- phase 2 study lymphoproliferative disorders: results of a prospective multicenter Efficacy and safety of rituximab in B-cell post-transplantation (2011) (0)
- Book Review Molecular Haematology Edited by Drew Provan and John Gribben. 240 pp., illustrated. Malden, Mass., Blackwell Science, 2000. $190. 0-632-05037-3 (2000) (0)
- Reply to S. Fuji. (2019) (0)
- Impact of 18 f-Fluoro-Deoxyglucose Positron Emission Tomography Imaging in the Management of Mantle Cell Lymphoma (2015) (0)
- Pharmacokinetic and pharmacodynamic relationships of copanlisib in patients with non-Hodgkin lymphoma and advanced solid tumors (2018) (0)
- Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma (2022) (0)
- ABCL-088 Subgroup Analysis in RE-MIND2: An Observational, Retrospective Cohort Study of Tafasitamab + Lenalidomide Versus Systemic Therapies in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. (2022) (0)
- Abstract 56: MSK-ACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with lymphoma (2022) (0)
- How FDG PET/CT can improve enhanced CT interpretation for staging malignant lymphoma: The synergistic combination of morphologic and metabolic data (2013) (0)
- Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Program LNH2003, (2011) (0)
- A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers (2018) (0)
- BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: SINGLE‐CENTER REAL‐WORLD EXPERIENCE (2021) (0)
- [Prognostic factors in lymphomas]. (2010) (0)
- METABOLIC TUMOR IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R ‐ CHOP – FROM REMARC, A LYSA STUDY (2021) (0)
- lymphomas Prognostic significance of survivin expression in diffuse large B-cell (2013) (0)
- EE458 Health Care Resource Utilization and Costs of CAR T-Cell Therapy in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Claims Database Analysis in the US (2022) (0)
- Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study (2018) (0)
- [Chronic lymphoproliferative disorders]. (2002) (0)
- Efficacy and Safety of Once Weekly Epoetin Beta 30 000 IU in 691 Patients with Solid or Lymphoid Malignancies Receiving Chemotherapy: Results from the NAUTICA Study. (2006) (0)
- Poster: ABCL-088 Subgroup Analysis in RE-MIND2: An Observational, Retrospective Cohort Study of Tafasitamab + Lenalidomide Versus Systemic Therapies in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2022) (0)
- Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies. (2017) (0)
- P53 Prevents TCR-Dependent Peripheral T-Cell Lymphomagenesis From Chronically Stimulated T Cells. (2012) (0)
- Molecular Characterization of the T(14;18)(q32;q21) Involving the IGH Locus and the MALT1 Gene in MALT Lymphomas (2008) (0)
- Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study (2019) (0)
- EFFICACY AND SAFETY OF RITUXIMAB IN B-CELL POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: RESULTS OF A PROSPECTIVE MULTICENTRE PHASE II STUDY Running head: Rituximab in PTLD (2017) (0)
- CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) (2021) (0)
- New drugs for old targets (2019) (0)
- Faculty Opinions recommendation of Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. (2010) (0)
- Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system. (2016) (0)
- Cytokine Gene Polymorphisms and Outcome of Patients with Hodgkin Lymphoma: A Prospective Study of the Groupe D’Etude Des Lymphomes De L’Adulte (2008) (0)
- Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma (2022) (0)
- Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]. (2021) (0)
- Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study (2013) (0)
- Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study. (2012) (0)
- In Vivo Purge with Rituximab before Harvest Does Not Alter the Graft nor the Hematologic Recovery after Transplant. (2004) (0)
- Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL) : Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). (2012) (0)
- Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab. (2014) (0)
- [Not Available]. (2016) (0)
- Mediastinal Large B-Cell Lymphoma : A unique subset of diffuse large B-cell lymphoma with an expression signature resembling that of Hodgkin ’ s Reed-Sternberg Cells (2004) (0)
- Mise au point sur les indications du G-CSF pégylé (2009) (0)
- PB2145 POMALIDOMIDE AND DEXAMETHASONE IN RELAPSING POEMS SYNDROME: A FRENCH REPORT OF 5 CASES (2019) (0)
- Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade (2021) (0)
- Molecular profiling of diffuse large B-cell lymphoma reveals discrete clusters including one characterized by host inflammatory response (2004) (0)
- Letter to Blood Chronic Borrelia burgdorferi infection triggers NKT lymphomagenesis (2018) (0)
- 1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors (2020) (0)
- LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL) (2021) (0)
- Prognostic value of etoposide area under the curve (AUC) in lymphoma patients treated with BEAM regimen and ASCT: Multicenter study of Groupe d’Etudes des Lymphomes de l’Adulte (GELA). (2012) (0)
- Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas (2021) (0)
- Human Vδ1+ γδ Peripheral T-Cell Lymphoma/Leukemia are Derived from Natural Killer T (NKT) Cells and Might be Treated with Blocking Anti-CD1d Antibody (2016) (0)
- Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma, (2011) (0)
- [Contribution of dual CD13/CD14 markers in combination with CD34 for the collection of peripheral hematopoietic stem cells]. (1997) (0)
- Long-Term Prognostic Significance of Response in Hodgkin Lymphoma Before Autologous Stem Cell Transplantation :Results of the Prospective Multicenter H96 Trial by the GELA/SFGM-TC Study Group (2011) (0)
- S100 TREATMENT-DEPENDENCE OF HIGH-RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA (2019) (0)
- IPI24 supplemental material submitted (2015) (0)
- 5.51 Is Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) in CLL Still Under Debate? A Population Matched Analysis Between Auto-HSCT and Rituximab-Fludarabine-Cyclophosphamide in First-Line CLL Patients (2011) (0)
- Multiple Secondary Genetic Events Inducing Histologic Progression (HP) of Non-MALT Marginal Zone Lymphoma (MZL): An Integrated Genomic Analysis of Genome-Wide Copy-Number-Changes (CNC) and Transcriptomic Data. (2008) (0)
- Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2™ with the Cllear and Lyon-Sud Rw Databases (2021) (0)
- Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion (2021) (0)
- Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort (2019) (0)
- Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03–6B GELA Study. (2012) (0)
- Effectiveness of epoetin beta 30,000 UI once weekly (QW) for treatment of anemia in solid tumor patients under chemotherapy (2007) (0)
- Erratum to: BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib (2017) (0)
- Antibody Therapy Maintenance in Follicular Lymphoma. (2020) (0)
- Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients (2017) (0)
- Gene Expression Profiling Analysis in Splenic Marginal Zone Lymphoma Allows To Predict Survival and Histological Transformation. (2004) (0)
- No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials (2014) (0)
- PF294 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY (2019) (0)
- Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2020) (0)
- Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study. (2022) (0)
- functions to regulate stromal cell-dependent lymphopoiesis CD 10 / NEP is expressed on Thy-1 low B 220 + murine B-cell progenitors (2003) (0)
- Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study (2021) (0)
- ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL) (2021) (0)
- CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (ELEVATE-TN) (2021) (0)
- VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information. (2006) (0)
- Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy (2020) (0)
- infradiaphragmatic Hodgkin Lymphoma: Long-term Outcome Improved By Radiotherapy–chemiotherapy Vs Chemiotherapy Alone : 172 (2015) (0)
- Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility (2019) (0)
- Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies (2016) (0)
- Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials. (2022) (0)
- [Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. (2017) (0)
- RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY (2019) (0)
- Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis. (2006) (0)
- A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma (2022) (0)
- Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results Fro (2022) (0)
- t(11;14) with BCL1-IGH rearrangement. (2003) (0)
- NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry (2020) (0)
- Genome-Wide Association Study of the Human Genetic Factors Influencing the Risk of Adverse Events during Idelalislib Therapy in Patients with Relapsed Indolent Lymphoma (2016) (0)
- Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study (2020) (0)
- Through the Glass Ceiling. (2018) (0)
- CHARACTERISTICS AND OUTCOMES OF RELAPSED FOLLICULAR LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA (2017) (0)
- ROLE OF UP‐FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS (2017) (0)
- Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL) (2021) (0)
- Treatment of Non-Hodgkin’s Diffuse Large Cell Lymphomas (1995) (0)
- Long term efficacy of rituximab in follicular lymphoma (FL) and polymorphism in IgG Fc receptor Fc{gamma}RIIIa/Fc{gamma}RIIa genes (2005) (0)
- A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study (2017) (0)
- Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing (2022) (0)
- Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe (2022) (0)
- Toll-Like Receptor Profiles In Splenic Marginal Zone B-Cell Lymphoma and Splenic Diffuse Red Pulp B-Cell Lymphoma (2013) (0)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (2014) (0)
- CO67 Tafasitamab Plus Lenalidomide (TAFA+LEN) Versus Pola-BR, R2, and CAR-T in Non-Transplant Eligible (NTE) Relapsed/Refractory (R/R) DLBCL: A Post Hoc Analysis of the RE-MIND2 Study Comparing Multiple Cohort-Balancing Approaches (2022) (0)
- Bam Conditioning Before Autologous Stem Cell Transplantation for Lymphoma: A Retrospective Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (sfgm-Tc) (2017) (0)
- Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5 (2021) (0)
- Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance (2021) (0)
- New Agents to Treat Chronic Lymphocytic Leukemia. (2016) (0)
- Toward A Paradigm Shift in Cancer Research & Innovation for Patients in France (2017) (0)
- Bronchiolite lymphocytaire clonale B isolée : diagnostic par analyse de réarrangement génique (2013) (0)
- Lymphome de type Mucosa-Associated Lymphoid Tissue , (MALT) pulmonaire, puis gastrique (2016) (0)
- The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe (2022) (0)
- Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. (2019) (0)
- Breakthrough in supportive cancer care : introducing Pegfilgrastim (2004) (0)
- ONE‐YEAR REAL‐LIFE TARGETED NEXT GENERATION SEQUENCING FOR LYMPHOMA DIAGNOSIS: STUDY OF PATIENTS FROM THE FRENCH LYMPHOMA NETWORK IN RHÔNE‐ALPES (2019) (0)
- Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (2020) (0)
- Long term efficacy of rituximab in follicular lymphoma (FL) and polymorphism in IgG Fc receptor FcγRIIIa/FcγRIIa genes (2005) (0)
- patients with distinct clinical features and outcome Nonfollicular small B-cell lymphomas: a heterogeneous group of (2011) (0)
- PET-CT before autologous stem cell transplant in follicular lymphoma: coming too late? (2022) (0)
- Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation (2022) (0)
- Pr Bertrand Coiffier (2019) (0)
- Antimicrobial resistance of Gram-negative bacteria isolated from blood in HSCT patients: a multinational prospective study on behalf of the EBMT-IDWP. (2016) (0)
- Epigenetics and Adult Acute Myeloid Leukemia (2016) (0)
- Follicular lymphoma: twenty years of progress, and multiple challenges (2019) (0)
- Correction to: Aggressive Lymphomas (2019) (0)
- [Hodgkin's disease: biology can help the physician towards new prognostic factors and new therapeutic approaches]. (2001) (0)
- Isolated lymphocytic bronchiolitis with B cell clonality: Diagnosis in 3 cases using immunoglobulin gene rearrangement analysis (2012) (0)
- Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome (2012) (0)
- Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University (2018) (0)
- [Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital]. (2017) (0)
- Performances of targeted RNA-sequencing for the analysis of fusion transcripts, gene mutation and expression in haematological malignancies (2020) (0)
- The upper ECHELON against T-cell lymphoma. (2022) (0)
- Conservative treatment of primary gastric B-cell lymphoma of MALT-type arising in the setting of HIV infection and posttransplantation (2001) (0)
- Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group (2022) (0)
- 11 New biological determinants in lymphoma (2010) (0)
- Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the P (2022) (0)
- Maladie de Hodgkin : Diagnostic, classification internationale à visée pronostique, évolution, principes du traitement (1998) (0)
- [Lymphoma classification: a collection for specialists or a medical progress?]. (2004) (0)
- [Breast cancer: the end of big arms, sequelae, and mutilations]. (1990) (0)
- 0Effects of physical exercise after allogenic stem cell transplantation: A five years retrospective study (2018) (0)
- Cancer chemotherapeutic error in hospitalized patients: Attributable damages and extra costs. (2010) (0)
- Short title: IL -10 polymorphisms and lymphoma outcome (2003) (0)
- [Buprenorphin and benzodiazepines, an association with high risk. Reality of co-prescriptions by the general practitioners]. (2010) (0)
- Diffuse Large B-Cell Lymphoma. Reply. (2021) (0)
- Poster Presentations (2020) (0)
- Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes (2021) (0)
- No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib (2020) (0)
- [Mucosa-associated lymphoid tissue-derived (MALT) lymphoma]. (2016) (0)
- Paper 81946 abstract 160359 0 (2015) (0)
- PS1303 CHRONIC TCR STIMULATION PROMOTES PERIPHERAL T-CELL LYMPHOMAGENESIS AND INDUCES ADDICTION TO SYK AND NK RECEPTOR SIGNALING (2019) (0)
- Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (2020) (0)
- Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases (2017) (0)
- 13 Diffuse large B-cell lymphoma (2010) (0)
- A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study (2022) (0)
- Outcome in Multiple Myeloma Patients Treated in the Era of Modern Therapies Who Were Admitted to Intensive Care: A Retrospective Analysis from a Teaching Hospital between 2014 and 2019 (2022) (0)
- Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study (2023) (0)
- A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi) (2022) (0)
- Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of Irakimids and BCL2 Inhibition (2022) (0)
- CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMA (2021) (0)
- Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy (2022) (0)
- Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2022) (0)
- BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. (2022) (0)
- Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III P (2022) (0)
- Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study (2022) (0)
- Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study (2023) (0)
- High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles (2020) (0)
- Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment (2023) (0)
- Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial (2022) (0)
- High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network (2022) (0)
- Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Zuma-7 (2022) (0)
- LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients (2022) (0)
- Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. (2022) (0)
- TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. (2023) (0)
- BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas (2022) (0)
- Bridging Radiation Rapidly and Effectively Cytoreduces High Risk Relapsed/Refractory Aggressive B-Cell Lymphomas Prior to Chimeric Antigen Receptor T-Cell Therapy. (2022) (0)
- Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2022) (0)
- REAL‐WORLD TREATMENT PATTERNS AND OUTCOMES OF 3455 PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA PATIENTS IN US ROUTINE CLINICAL PRACTICE (2021) (0)
- L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years (2022) (0)
- Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm (2022) (0)
- Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study (2022) (0)
- Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study (2022) (0)
- Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies (2022) (0)
- Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma (2022) (0)
- Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting (2023) (0)
- Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis (2022) (0)
- Prospective Geriatric Assessment and Geriatric Consultation in CAR T-cell Therapy for Older Lymphoma Patients. (2023) (0)
- T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma (2022) (0)
- Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy (2022) (0)
- Positron emission tomography-computed tomography before autologous stem cell transplant in follicular lymphoma: coming too late? (2022) (0)
- Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma (2012) (0)
- Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study) (2019) (0)
- Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBLC). (2007) (0)
- Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study (2022) (0)
- Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma (2013) (0)
This paper list is powered by the following services:
Other Resources About Gilles Salles
What Schools Are Affiliated With Gilles Salles?
Gilles Salles is affiliated with the following schools:
